Specialty Natural Products Public (SNPS) Fundamentals 2026 — P/E 15.3x, Revenue Analysis | SniperIQ
Specialty Natural Products Public (SNPS) is a TH-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ฿1.8B, trading at ฿4.50 on the SET. This SniperIQ fundamentals page covers Specialty Natural Products Public's valuation (P/E 15.3x, P/B 2.0x), profitability (net margin 21.3%), revenue (฿554M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Specialty Natural Products Public's market cap?
Specialty Natural Products Public (SNPS) has a market capitalization of approximately ฿1.8B, trading at ฿4.50 on the SET. Market cap moves with the live share price.
What is Specialty Natural Products Public's P/E ratio?
Specialty Natural Products Public's trailing twelve-month P/E ratio is 15.3x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Specialty Natural Products Public?
Specialty Natural Products Public runs a net profit margin of 21.3%, a gross margin of 42.2%, and an operating margin of 24.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Specialty Natural Products Public generate?
Specialty Natural Products Public reported revenue of ฿554M for fiscal year 2025, with net income of ฿112M and earnings per share (EPS) of 0.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Specialty Natural Products Public pay a dividend?
Specialty Natural Products Public offers a trailing dividend yield of about 5.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Specialty Natural Products Public financially healthy?
Specialty Natural Products Public carries a debt-to-equity ratio of 0.00x and a current ratio of 9.74x, with a market beta of -0.13. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Specialty Natural Products Public a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Specialty Natural Products Public (SNPS) the key facts are: market cap ฿1.8B, P/E 15.3x, revenue ฿554M, 52-week range 4.16-5.05. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Specialty Natural Products Public's full fundamentals live
Get Specialty Natural Products Public's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.